Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
The deal will happen. Iron deficiency ain’t going anywhere and STX have the worlds most combined convenient and effective therapeutic for the worlds biggest deficiency. The impatient will sell. Traders may sell. But this share rises rapidly and it is very easy to get locked out.
Just if. Not when. And as the virus takes off again, you reckon hospitals are keen on IV iron. Nope. We have a tablet as effective, less costly and keeps people out of clinics and away from the virus.
The writing is on the wall for IV iron.
The world is now a different place. Working from home will become common place. Doctor consultations over the phone are common place now.
And you reckon IV iron requiring hospitalisation can compete with a tablet !
I know where I’m putting my money.
Shield Therapeutics*
Interims in line, awaiting US partner
Interim results to 30 June largely reflected the licensing income from ASK Pharm in China. Revenues were £8.9m, with royalties of c.£0.2m despite disruptions due to COVID-19 and £8.7m of milestone payments. This resulted in an adjusted net profit of £4.4m (vs a loss of £3.4m in H1 2019). A net cash inflow of £2.4m in the period resulted in cash at 30 June of £6.5m, providing a cash runway to Q1 2021. The figure excludes potential significant up-front payments and milestones for the US, for which a licensing deal is still expected. An order to its contract manufacturer for US launch stocks for delivery by year-end should provide comfort despite the understandable shortage of information pertaining to licensing discussions. We leave our forecasts unchanged (excludes potential upfront payments from US licensing deal) and reiterate our 350p target price.
?Interim results in brief. Revenues rose to £8.9m (vs. £0.4m), comprising £8.7m of milestone payments and c.£0.2m of royalties. Net profit of £3.1m (vs. a restated net loss of £4.2m in H1 2019) implied an adjusted net profit of £4.4m (vs a loss of £2.9m). Period- end cash was £6.5m, up from £4.1m at 31 December 2019, implying an underlying (ex- upfront) cashburn of c.£4.2m in the period (excludes the net £7.8m cash receipt from Chinese licensing rights and the £1.2m of fees paid to advisers for the China licence).
?Outlook – US licensing deal. Shield is in discussions with a number of potential partners, some of which have submitted non-binding offers. Whilst details of the ongoing discussions are understandably not disclosed, confirmation that Shield has ordered launch stocks of US packs of Accrufer from its contract manufacturer for year-end 2020 should serve as a strong indication that a licensing deal is close.
?Regulatory update. Indications from the Chinese regulatory authority that approval could be gained from short-term Phase III study in Inflammatory Bowel Disease without the need for a pharmacokinetic study or Phase III clinical study in Chronic Kidney Disease is positive and indicates a potential 2023 launch. The regulatory approval process in Australia is also underway, with a potential approval by year-end.
?Cash runway extends into Q1 2021 with year-end 2020 cash of £1.2m dependent on the timing of R&D expenses relating to the paediatric Feraccru study. This excludes the potential for substantial upfront payments from a US licence deal and other smaller markets where Shield has entered discussions.
?Valuation. We reiterate our 350p target price (DCF). This excludes the potential value of milestone payments from a US licensing deal, which we estimate could be c.$50m upfront with $100m+ of commercial milestones.
Great update IMO
Companies signing confidentiality agreements in the US. So not if , just when.
China market is massive so good news that it will happen quicker.
Norgine going up 50% during Covid pandemic is fantastic.
Stunned this still is around this price.
Oh Graham ... the old deramp but pretend to hold technique .... oldest one in the book !
And the vaccine argument is a joke. SNG works against Viruses in general, and we have a flu jab offered every year. People still get flu FFS. SNG will be a therapeutic used moving forward , Covid vaccine or not.
I feel the bonus of the COOD results will be that it will reinforce that SNG 001 has general anti viral properties. Not just Covid. People don’t seem to get it.
Then Governments will hopefully line up to stockpile it for future pandemics.. which will have to be fully expected now.